📣 ¡Grandes noticias a compartir! 1️⃣ Cerramos cuarta ronda de inversión de 2,2M€. Gracias al apoyo de nuestros inversores superamos el objetivo de 1,6M€ marcado en un inicio. 2️⃣ Estos fondos nos permitirán continuar los ensayos clínicos con pacientes adultos ya en marcha en el Hospital de la Santa Creu i Sant Pau, e iniciar los ensayos clínicos con pacientes de #cáncerinfantil. 3️⃣ El prestigioso informe estadounidense de DelveInsight Business Research LLP ha reconocido nuestro fármaco (CEB-01) como una de las 100 terapias emergentes del mundo en el panorama del #sarcoma de tejidos blandos. Más información ➡️ https://lnkd.in/dXri7NE via La Vanguardia ¡Seguimos! 💪
CEBIOTEX
Biotecnología
Barcelona, Catalonia 1000 seguidores
Providing solutions for patients with cancer by helping surgeons in their oncological interventions.
Sobre nosotros
CEBIOTEX leverages nanofiber engineering to create a new medical product which can be infused with multiple agents, with special usefulness for low water solubility drugs. Proprietary technology allows to produce biocompatible-biodegradable membranes (protected by several patents in EU, USA and China), and without chemical interaction between the nanofiber polymer and the agent applied. First medical need targeted is in the field of Oncology: to reduce local recurrence and spreading of tumour cells, by improving local control of cancer after surgery. First product, CEB-01, is composed by our nanofiber membrane and the chemotherapeutic drug SN-38. CEB-01 is placed over the surgical bed after surgeon’s removal of a tumour mass, and immediately starts delivering SN-38 locally. It’s compatible with current standard of care, while offering a treatment option during a period of time when no other therapy can be administered (4 weeks right after surgery). An Orphan Drug Designation (ODD) for the treatment in Soft Tissue Sarcoma (STS) has been granted by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA). First program is focused on local treatment of STS. All preclinical work has been finished, GMP certification has been granted by AEMPS (Spanish Agency of Medications and Health Products) for manufacture of CEB-01 pharmaceutical form, and we have received in January, 2020 the official approval from the AEMPS to initiate Clinical trials in patients. The trials have already started at Hospital de Sant Pau in Barcelona, showing extremely promising results. Cebiotex started its activity in 2015 as a spin-off of UPC and Hospital Sant Joan de Déu de Barcelona.
- Sitio web
-
https://www.cebiotex.com/
Enlace externo para CEBIOTEX
- Sector
- Biotecnología
- Tamaño de la empresa
- De 2 a 10 empleados
- Sede
- Barcelona, Catalonia
- Tipo
- De financiación privada
- Fundación
- 2015
Ubicaciones
-
Principal
Plaça de Pau Vila, 1; Block A, 3rd Floor
Barcelona Tech City
Barcelona, Catalonia 08039, ES
Empleados en CEBIOTEX
-
Toni Perez
Chairman/member Adv Boards, Combioxin's Chief Medical Officer, Aptarion's Head Clinical Development, and drug clinical development consultant of…
-
Marc Ramis Castelltort
Investing & Building Ventures to Impact Children's Health | Managing Partner at Montana Impact Fund | Venture Capital
-
Imma Barber Turro
Pharmaceutical Executive, Entrepreneur, Consultant, Business Strategy, Interim Management, International.
-
Joan Bertran Llavina
Emprendedor, Co-fundador y CEO en CEBIOTEX S.L.
Actualizaciones
-
CEBIOTEX ha compartido esto
CEBIOTEX is pleased to inform you that the poster presented at #ASCO24 is available for preview. 📊 This presentation highlights the preliminary results obtained from the Phase I First-in-human CEB-01 trial in retroperitoneal #sarcomas. 💡 We invite you to check the website and learn how we are revolutionising the outcome of cancer surgery with CEB-01. CEB-01 is a membrane that is implanted after surgical resection, allowing for local release of chemotherapeutics such as SN-38 to prevent local recurrence of retroperitoneal tumours. 🔗 Access the full poster here: https://lnkd.in/gZB9FmSU #ASCO24 #CancerResearch #ClinicalOncology _________________________________________________________________________________ CEBIOTEX se complace en informarles que el póster presentado en #ASCO24 está disponible para su visualización. 📊 Esta presentación destaca los resultados preliminares obtenidos del ensayo clínico fase I con CEB-01 en sarcomas retroperitoneales. 💡 Los invitamos a visitar nuestro sitio web y conocer cómo estamos revolucionando los resultados de la cirugía contra el cáncer con CEB-01. CEB-01 es una membrana que se implanta después de la resección quirúrgica, permitiendo la liberación local de quimioterapéuticos como el SN-38 para prevenir la recurrencia local de tumores retroperitoneales. 🔗 Acceda al póster completo aquí: https://lnkd.in/gZB9FmSU #ASCO24 #InvestigaciónContraElCáncer #OncologíaClínica
-
CEBIOTEX is pleased to inform you that the poster presented at #ASCO24 is available for preview. 📊 This presentation highlights the preliminary results obtained from the Phase I First-in-human CEB-01 trial in retroperitoneal #sarcomas. 💡 We invite you to check the website and learn how we are revolutionising the outcome of cancer surgery with CEB-01. CEB-01 is a membrane that is implanted after surgical resection, allowing for local release of chemotherapeutics such as SN-38 to prevent local recurrence of retroperitoneal tumours. 🔗 Access the full poster here: https://lnkd.in/gZB9FmSU #ASCO24 #CancerResearch #ClinicalOncology _________________________________________________________________________________ CEBIOTEX se complace en informarles que el póster presentado en #ASCO24 está disponible para su visualización. 📊 Esta presentación destaca los resultados preliminares obtenidos del ensayo clínico fase I con CEB-01 en sarcomas retroperitoneales. 💡 Los invitamos a visitar nuestro sitio web y conocer cómo estamos revolucionando los resultados de la cirugía contra el cáncer con CEB-01. CEB-01 es una membrana que se implanta después de la resección quirúrgica, permitiendo la liberación local de quimioterapéuticos como el SN-38 para prevenir la recurrencia local de tumores retroperitoneales. 🔗 Acceda al póster completo aquí: https://lnkd.in/gZB9FmSU #ASCO24 #InvestigaciónContraElCáncer #OncologíaClínica
Póster de presentación de la reunión anual de ASCO 2024
https://www.cebiotex.com/es/
-
CEBIOTEX is excited to participate in the #ASCO24 event in Chicago! The global meeting point for #oncology professionals, where we will share the advances and successes of our clinical trial with other companies and professionals in the sector. We invite you to visit us and learn how we are revolutionising the outcome of cancer surgery with the drug CEB-01: a local release membrane of the therapeutic chemical SN-38 that serves to eliminate any residual local cancer activity following surgery in retroperitoneal #sarcomas. Get to know us at the link below! We would love to connect with you https://lnkd.in/dFtXQ_ZU ¡Desde CEBIOTEX estamos emocionados de participar en el evento #ASCO24 en Chicago! El punto de encuentro mundial para profesionales de la #oncología, donde compartiremos los avances y éxitos de nuestro ensayo clínico junto con los proyectos de otras empresas y profesionales del sector. Te invitamos a visitarnos y conocer cómo estamos revolucionando el cuidado oncológico con el fármaco CEB-01: una membrana de liberación loco-regional del químico SN-38 que sirve para prevenir la aparición local en #sarcomas retroperitoneales. #ASCO24 #CancerResearch #ClinicalOncology #CancerTreatment #fundraising
-
Cebiotex wishes you a Merry Christmas and a Happy New Year 2024!
Cebiotex - Merry Christmas
https://www.youtube.com/
Páginas similares
Buscar empleos
Financiación
Última ronda
Crowdfunding equitativo914.535,00 US$